What’s Next? Five Things To Look Out For In March
Viatris Eyes Approval For Symbicort Rival; Polpharma Nears Natalizumab Landmark
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
